Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jul. 01, 2023 | Jul. 17, 2023 | |
Document and Entity Information | ||
Entity Registrant Name | SILICON LABORATORIES INC. | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jul. 01, 2023 | |
Document Transition Report | false | |
Entity File Number | 000-29823 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 74-2793174 | |
Entity Address, Address Line One | 400 West Cesar Chavez | |
Entity Address, City or Town | Austin | |
Entity Address, State or Province | TX | |
Entity Address, Postal Zip Code | 78701 | |
City Area Code | 512 | |
Local Phone Number | 416-8500 | |
Title of 12(b) Security | Common Stock, $0.0001 par value | |
Trading Symbol | SLAB | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 31,864,364 | |
Entity Central Index Key | 0001038074 | |
Current Fiscal Year End Date | --12-30 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jul. 01, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 234,813 | $ 499,915 |
Short-term investments | 271,063 | 692,024 |
Accounts receivable, net | 98,256 | 71,437 |
Inventories | 145,523 | 100,417 |
Prepaid expenses and other current assets | 71,322 | 97,570 |
Total current assets | 820,977 | 1,461,363 |
Property and equipment, net | 152,358 | 152,016 |
Goodwill | 376,389 | 376,389 |
Other intangible assets, net | 72,003 | 84,907 |
Other assets, net | 97,072 | 94,753 |
Total assets | 1,518,799 | 2,169,428 |
Current liabilities: | ||
Accounts payable | 55,102 | 89,860 |
Revolving line of credit | 80,000 | |
Deferred revenue and returns liability | 11,105 | 6,780 |
Other current liabilities | 72,339 | 89,136 |
Total current liabilities | 218,546 | 185,776 |
Convertible debt, net | 529,573 | |
Other non-current liabilities | 41,356 | 49,071 |
Total liabilities | 259,902 | 764,420 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Preferred stock - $0.0001 par value; 10,000 shares authorized; no shares issued | ||
Common stock - $0.0001 par value; 250,000 shares authorized; 31,861 and 31,994 shares issued and outstanding at July 1, 2023 and December 31, 2022, respectively | 3 | 3 |
Retained earnings | 1,262,984 | 1,415,693 |
Accumulated other comprehensive loss | (4,090) | (10,688) |
Total stockholders' equity | 1,258,897 | 1,405,008 |
Total liabilities and stockholders' equity | $ 1,518,799 | $ 2,169,428 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands | Jul. 01, 2023 | Dec. 31, 2022 |
Condensed Consolidated Balance Sheets | ||
Preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Preferred stock, shares authorized | 10,000 | 10,000 |
Preferred stock, shares issued | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized | 250,000 | 250,000 |
Common stock, shares issued | 31,861 | 31,994 |
Common stock, shares outstanding | 31,861 | 31,994 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 01, 2023 | Jul. 02, 2022 | Jul. 01, 2023 | Jul. 02, 2022 | |
Condensed Consolidated Statements of Income | ||||
Revenues | $ 244,866 | $ 263,150 | $ 491,653 | $ 496,964 |
Cost of revenues | 101,091 | 99,247 | 194,018 | 177,289 |
Gross profit | 143,775 | 163,903 | 297,635 | 319,675 |
Operating expenses: | ||||
Research and development | 85,902 | 83,511 | 175,298 | 161,053 |
Selling, general and administrative | 40,706 | 49,013 | 85,597 | 93,660 |
Operating expenses | 126,608 | 132,524 | 260,895 | 254,713 |
Operating income | 17,167 | 31,379 | 36,740 | 64,962 |
Other income (expense): | ||||
Interest income and other, net | 7,780 | 3,445 | 12,616 | 4,944 |
Interest expense | (1,596) | (1,667) | (3,252) | (3,347) |
Income before income taxes | 23,351 | 33,157 | 46,104 | 66,559 |
Provision for income taxes | 12,338 | 10,994 | 20,091 | 22,683 |
Equity-method earnings (loss) | (57) | (28) | (1,090) | 1,166 |
Net income | $ 10,956 | $ 22,135 | $ 24,923 | $ 45,042 |
Earnings per share: | ||||
Basic (in dollars per share) | $ 0.35 | $ 0.62 | $ 0.78 | $ 1.22 |
Diluted (in dollars per share) | $ 0.33 | $ 0.60 | $ 0.75 | $ 1.18 |
Weighted-average common shares outstanding: | ||||
Basic | 31,614 | 35,722 | 31,786 | 36,862 |
Diluted | 32,926 | 36,604 | 33,339 | 38,063 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 01, 2023 | Jul. 02, 2022 | Jul. 01, 2023 | Jul. 02, 2022 | |
Condensed Consolidated Statements of Comprehensive Income | ||||
Net income | $ 10,956 | $ 22,135 | $ 24,923 | $ 45,042 |
Net changes to available-for-sale securities | ||||
Unrealized gains (losses) arising during the period | 1,385 | (3,013) | 4,383 | (12,705) |
Reclassification for losses included in net income | 1,859 | 374 | 4,474 | 423 |
Net changes to cash flow hedges | ||||
Unrealized losses arising during the period | (580) | (3,001) | (544) | (3,545) |
Reclassification for losses included in net income | 186 | 1,092 | 157 | 1,092 |
Other comprehensive income (loss), before tax | 2,850 | (4,548) | 8,470 | (14,735) |
Provision (benefit) for income taxes | 477 | (959) | 1,872 | (3,099) |
Other comprehensive income (loss) | 2,373 | (3,589) | 6,598 | (11,636) |
Comprehensive income | $ 13,329 | $ 18,546 | $ 31,521 | $ 33,406 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands | Common Stock | Additional Paid-In Capital | Retained Earnings Cumulative effect of adoption of accounting standard | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Cumulative effect of adoption of accounting standard | Total |
Balance at Jan. 01, 2022 | $ 4 | $ 0 | $ (59,963) | $ 2,214,839 | $ (2,419) | $ (59,963) | $ 2,212,424 |
Balance (in shares) at Jan. 01, 2022 | 38,481 | ||||||
Increase (Decrease) in Stockholders' Equity | |||||||
Net income | 45,042 | 45,042 | |||||
Other comprehensive income (loss) | (11,636) | (11,636) | |||||
Stock issuances, net of shares withheld for taxes | (7,593) | (7,593) | |||||
Stock issuances, net of shares withheld for taxes (in shares) | 301 | ||||||
Repurchases of common stock | $ (1) | (19,675) | (580,522) | (600,198) | |||
Repurchases of common stock (in shares) | (4,559) | ||||||
Stock-based compensation | 27,268 | 27,268 | |||||
Balance at Jul. 02, 2022 | $ 3 | 0 | 1,619,396 | (14,055) | 1,605,344 | ||
Balance (in shares) at Jul. 02, 2022 | 34,223 | ||||||
Balance at Apr. 02, 2022 | $ 4 | 0 | 2,018,117 | (10,466) | 2,007,655 | ||
Balance (in shares) at Apr. 02, 2022 | 37,204 | ||||||
Increase (Decrease) in Stockholders' Equity | |||||||
Net income | 22,135 | 22,135 | |||||
Other comprehensive income (loss) | (3,589) | (3,589) | |||||
Stock issuances, net of shares withheld for taxes | 1,161 | 1,161 | |||||
Stock issuances, net of shares withheld for taxes (in shares) | 159 | ||||||
Repurchases of common stock | $ (1) | (15,561) | (420,856) | (436,418) | |||
Repurchases of common stock (in shares) | (3,140) | ||||||
Stock-based compensation | 14,400 | 14,400 | |||||
Balance at Jul. 02, 2022 | $ 3 | 0 | 1,619,396 | (14,055) | 1,605,344 | ||
Balance (in shares) at Jul. 02, 2022 | 34,223 | ||||||
Balance at Dec. 31, 2022 | $ 3 | 0 | 1,415,693 | (10,688) | $ 1,405,008 | ||
Balance (in shares) at Dec. 31, 2022 | 31,994 | 31,994 | |||||
Increase (Decrease) in Stockholders' Equity | |||||||
Net income | 24,923 | $ 24,923 | |||||
Other comprehensive income (loss) | 6,598 | 6,598 | |||||
Stock issuances, net of shares withheld for taxes | (8,524) | (8,524) | |||||
Stock issuances, net of shares withheld for taxes (in shares) | 359 | ||||||
Repurchases of common stock | (19,330) | (177,632) | (196,962) | ||||
Repurchases of common stock (in shares) | (1,412) | ||||||
Stock-based compensation | 31,418 | 31,418 | |||||
Convertible debt activity | (3,564) | (3,564) | |||||
Convertible debt activity (in shares) | 920 | ||||||
Balance at Jul. 01, 2023 | $ 3 | 0 | 1,262,984 | (4,090) | $ 1,258,897 | ||
Balance (in shares) at Jul. 01, 2023 | 31,861 | 31,861 | |||||
Balance at Apr. 01, 2023 | $ 3 | 0 | 1,425,914 | (6,463) | $ 1,419,454 | ||
Balance (in shares) at Apr. 01, 2023 | 31,997 | ||||||
Increase (Decrease) in Stockholders' Equity | |||||||
Net income | 10,956 | 10,956 | |||||
Other comprehensive income (loss) | 2,373 | 2,373 | |||||
Stock issuances, net of shares withheld for taxes | (1,593) | (1,593) | |||||
Stock issuances, net of shares withheld for taxes (in shares) | 261 | ||||||
Repurchases of common stock | (9,597) | (173,886) | (183,483) | ||||
Repurchases of common stock (in shares) | (1,317) | ||||||
Stock-based compensation | 14,754 | 14,754 | |||||
Convertible debt activity | (3,564) | (3,564) | |||||
Convertible debt activity (in shares) | 920 | ||||||
Balance at Jul. 01, 2023 | $ 3 | $ 0 | $ 1,262,984 | $ (4,090) | $ 1,258,897 | ||
Balance (in shares) at Jul. 01, 2023 | 31,861 | 31,861 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 6 Months Ended | |
Jul. 01, 2023 | Jul. 02, 2022 | |
Operating Activities | ||
Net income | $ 24,923 | $ 45,042 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities of continuing operations: | ||
Depreciation of property and equipment | 12,441 | 10,561 |
Amortization of other intangible assets | 12,904 | 19,194 |
Amortization of debt issuance costs | 960 | 994 |
Loss on extinguishment of convertible debt | 3 | |
Stock-based compensation expense | 31,377 | 27,264 |
Equity-method (earnings) loss | 1,090 | (1,166) |
Deferred income taxes | (6,403) | (9,344) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (26,819) | 26,207 |
Inventories | (45,064) | (24,714) |
Prepaid expenses and other assets | 32,963 | (25,286) |
Accounts payable | (30,003) | 25,606 |
Other current liabilities and income taxes | (26,220) | (3,418) |
Deferred revenue and returns liability | 4,326 | (3,153) |
Other non-current liabilities | (1,975) | (4,416) |
Net cash provided by (used in) operating activities of continuing operations | (15,500) | 83,374 |
Investing Activities | ||
Purchases of marketable securities | (81,427) | (554,267) |
Sales of marketable securities | 339,555 | 27,404 |
Maturities of marketable securities | 171,691 | 511,296 |
Purchases of property and equipment | (13,462) | (12,322) |
Purchases of other assets | (215) | |
Net cash provided by (used in) investing activities of continuing operations | 416,142 | (27,889) |
Financing Activities | ||
Proceeds from revolving line of credit | 80,000 | |
Payments on debt | (536,124) | (21) |
Repurchases of common stock | (201,095) | (579,040) |
Payment of taxes withheld for vested stock awards | (16,310) | (13,958) |
Proceeds from the issuance of common stock | 7,785 | 6,365 |
Net cash used in financing activities of continuing operations | (665,744) | (586,654) |
Discontinued Operations | ||
Operating activities | 0 | (38,604) |
Net cash used in discontinued operations | 0 | (38,604) |
Decrease in cash and cash equivalents | (265,102) | (569,773) |
Cash and cash equivalents at beginning of period | 499,915 | 1,074,623 |
Cash and cash equivalents at end of period | $ 234,813 | $ 504,850 |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Jul. 01, 2023 | |
Significant Accounting Policies | |
Significant Accounting Policies | 1. Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information included herein contains all normal recurring accruals and adjustments which, in the opinion of management, are necessary to present fairly Silicon Laboratories Inc.’s (the “Company”) financial position, results of its operations, comprehensive income, stockholders’ equity and cash flows. The Condensed Consolidated Balance Sheet as of December 31, 2022 was derived from the Company’s audited Consolidated Financial Statements. All intercompany balances and transactions have been eliminated in consolidation. The condensed consolidated results of operations for the three and six months ended July 1, 2023 are not necessarily indicative of the results to be expected for the full year. These Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2022, included in the Company’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 1, 2023. The Company prepares financial statements on a 52- or 53-week fiscal year that ends on the Saturday closest to December 31. Fiscal 2023 will have 52 weeks and fiscal 2022 had 52 weeks. In a 52-week year, each fiscal quarter consists of 13 weeks. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Among the significant estimates affecting the financial statements are those related to inventories, goodwill, acquired intangible assets, other long-lived assets, revenue recognition, stock-based compensation and income taxes. Actual results could differ from those estimates, and such differences could be material to the financial statements. The Company periodically reviews the assumptions used in its financial statement estimates. Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Substantially all of the Company’s contracts with customers contain a single performance obligation, the sale of mixed-signal integrated circuit (“IC”) products. This performance obligation is satisfied when control of the product is transferred to the customer, which typically occurs upon delivery. Unsatisfied performance obligations primarily represent contracts for products with future delivery dates. The Company has opted to not disclose the amount of unsatisfied performance obligations as these contracts have original expected durations of less than one year. The transaction price reflects the Company’s expectations about the consideration it will be entitled to receive from the customer and may include fixed or variable amounts. Variable consideration primarily includes sales made to distributors under agreements allowing certain rights of return, referred to as stock rotation, and credits issued to the distributor due to price protection. The Company estimates variable consideration at the most likely amount to which it expects to be entitled. The estimate is based on information available to the Company, including recent sales activity and pricing data. The Company applies a constraint to its variable consideration estimate which considers both the likelihood of a return and the amount of a potential price concession. Variable consideration that does not meet revenue recognition criteria is deferred. The Company records a right of return asset in prepaid expenses and other current assets for the costs of distributor inventory not meeting revenue recognition criteria. A corresponding deferred revenue and returns liability amount is recorded for unrecognized revenue associated with such costs. The Company’s products carry a one-year replacement warranty. Payments are typically due within 30 days of invoicing and do not include a significant financing component. |
Earnings Per Share
Earnings Per Share | 6 Months Ended |
Jul. 01, 2023 | |
Earnings Per Share | |
Earnings Per Share | 2. Earnings Per Share The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data): Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Net income $ 10,956 $ 22,135 $ 24,923 $ 45,042 Shares used in computing basic earnings per share 31,614 35,722 31,786 36,862 Effect of dilutive securities: Convertible debt and stock-based awards 1,312 882 1,553 1,201 Shares used in computing diluted earnings per share 32,926 36,604 33,339 38,063 Earnings per share: Basic $ 0.35 $ 0.62 $ 0.78 $ 1.22 Diluted $ 0.33 $ 0.60 $ 0.75 $ 1.18 The Company irrevocably elected to settle the principal amount of its convertible senior notes in cash and intended to settle any excess value in shares in the event of a conversion. In June 2023, the Company paid $535.0 million in cash and issued 0.9 million shares of common stock in connection with the conversions and redemptions of the 2025 convertible senior notes. For the three and six months ended July 1, 2023 and July 2, 2022, approximately 0.9 million, 0.6 million, 1.1 million, and 0.8 million shares, respectively, were included in the denominator for the calculation of diluted earnings per share (related to the not yet converted or redeemed convertible senior notes.) See Note 6, Debt, to the Condensed Consolidated Financial Statements for additional information. |
Fair Value of Financial Instrum
Fair Value of Financial Instruments | 6 Months Ended |
Jul. 01, 2023 | |
Fair Value of Financial Instruments | |
Fair Value of Financial Instruments | 3. Fair Value of Financial Instruments The fair values of the Company’s financial instruments are recorded using a hierarchical disclosure framework based upon the level of subjectivity of the inputs used in measuring assets and liabilities. The three levels are described below: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs other than Level 1 that are directly or indirectly observable, such as quoted prices for similar assets or liabilities and quoted prices in less active markets. Level 3 – Inputs are unobservable for the asset or liability and are developed based on the best information available in the circumstances, which might include the Company’s own data. 3. Fair Value of Financial Instruments (Continued) The following summarizes the valuation of the Company’s financial instruments (in thousands). The tables do not include either cash on hand or assets and liabilities that are measured at historical cost or any basis other than fair value. Fair Value Measurements at July 1, 2023 Using Quoted Prices in Significant Other Active Markets for Observable Identical Assets Inputs Description (Level 1) (Level 2) Total Cash equivalents: Money market funds $ 129,878 $ — $ 129,878 Total cash equivalents $ 129,878 $ — $ 129,878 Short-term investments: Corporate debt securities $ — $ 178,843 $ 178,843 Government debt securities — 92,220 92,220 Total short-term investments $ — $ 271,063 $ 271,063 Total $ 129,878 $ 271,063 $ 400,941 Fair Value Measurements at December 31, 2022 Using Quoted Prices in Significant Other Active Markets for Observable Identical Assets Inputs Description (Level 1) (Level 2) Total Cash equivalents: Money market funds $ 310,969 $ — $ 310,969 Corporate debt securities — 3,249 3,249 Total cash equivalents $ 310,969 $ 3,249 $ 314,218 Short-term investments: Corporate debt securities $ — $ 501,014 $ 501,014 Government debt securities — 191,010 191,010 Total short-term investments $ — $ 692,024 $ 692,024 Total $ 310,969 $ 695,273 $ 1,006,242 3. Fair Value of Financial Instruments (Continued) Valuation methodology The Company’s cash equivalents and short-term investments that are classified as Level 2 are valued using non-binding market consensus prices that are corroborated with observable market data; quoted market prices for similar instruments in active markets; quoted prices in less active markets; or pricing models, such as a discounted cash flow model, with all significant inputs derived from or corroborated with observable market data. The Company’s foreign currency derivative instruments are valued using discounted cash flow models. The assumptions used in preparing the valuation models include foreign exchange rates, forward and spot prices for currencies and market observable data of similar instruments. Contractual maturities of investments The Company’s available-for-sale investments are reported at fair value, with unrealized gains and losses, net of tax, recorded as a component of accumulated other comprehensive loss in the Condensed Consolidated Balance Sheet. The following summarizes the contractual underlying maturities of the Company’s available-for-sale investments at July 1, 2023 (in thousands): Fair Cost Value Due in one year or less $ 187,356 $ 184,252 Due after one year through five years 88,385 86,811 $ 275,741 $ 271,063 Unrealized Gains and Losses The available-for-sale investments that were in a continuous unrealized loss position, aggregated by length of time that individual securities have been in a continuous loss position, were as follows (in thousands): Less Than 12 Months 12 Months or Greater Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized As of July 1, 2023 Value Losses Value Losses Value Losses Corporate debt securities $ 12,019 $ (29) $ 144,341 $ (2,918) $ 156,360 $ (2,947) Government debt securities 50,211 (391) 42,008 (1,415) 92,219 (1,806) $ 62,230 $ (420) $ 186,349 $ (4,333) $ 248,579 $ (4,753) Less Than 12 Months 12 Months or Greater Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized As of December 31, 2022 Value Losses Value Losses Value Losses Corporate debt securities $ 307,085 $ (5,297) $ 185,467 $ (4,090) $ 492,552 $ (9,387) Government debt securities 76,651 (626) 100,209 (3,541) 176,860 (4,167) $ 383,736 $ (5,923) $ 285,676 $ (7,631) $ 669,412 $ (13,554) The gross unrealized losses as of July 1, 2023 and December 31, 2022 were due primarily to changes in market interest rates. At July 1, 2023 and December 31, 2022, there were no material unrealized gains associated with the Company’s available-for-sale investments. 3. Fair Value of Financial Instruments (Continued) The Company records an allowance for credit loss when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, the Company reviews factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of July 1, 2023, there were no material declines in the market value of available-for-sale investments due to credit-related factors. Fair values of other financial instruments The Company’s debt was recorded at cost, but measured at fair value for disclosure purposes. The fair value of the Company’s convertible senior notes was determined using observable market prices. The notes were traded in less active markets and were therefore classified as a Level 2 fair value measurement. As of December 31, 2022, the fair value of the notes was $671.9 million. No notes were outstanding as of July 1, 2023. The Company’s other financial instruments, including cash, accounts receivable and accounts payable, are recorded at amounts that approximate their fair values due to their short maturities. |
Derivative Financial Instrument
Derivative Financial Instruments | 6 Months Ended |
Jul. 01, 2023 | |
Derivative Financial Instruments | |
Derivative Financial Instruments | 4. Derivative Financial Instruments The Company uses derivative financial instruments to manage certain exposures to the variability of foreign currency exchange rates. The Company’s objective is to offset increases and decreases in expenses resulting from these exposures with gains and losses on the derivative contracts, thereby reducing volatility of earnings. The Company does not use derivative contracts for speculative or trading purposes. The Company recognizes derivatives, on a gross basis, in the Condensed Consolidated Balance Sheet at fair value. Cash flows from derivatives are classified according to the nature of the cash receipt or payment in the Condensed Consolidated Statement of Cash Flows. Cash Flow Hedges Foreign Currency Forward Contracts The Company uses foreign currency forward contracts to reduce the earnings impact that exchange rate fluctuations have on operating expenses denominated in currencies other than the U.S. dollar. Changes in the fair value of the contracts are recorded in accumulated other comprehensive income (loss) in the Condensed Consolidated Balance Sheet and subsequently reclassified into earnings in the period during which the hedged transaction is recognized. The reclassified amount is reported in the same financial statement line item as the hedged item. If the foreign currency forward contracts are terminated or can no longer qualify as hedging instruments prior to maturity, the fair value of the contracts recorded in accumulated other comprehensive income (loss) may be recognized in the Condensed Consolidated Statement of Income based on an assessment of the contracts at the time of termination. The Company has entered into foreign currency forward contracts for a portion of its forecasted operating expenses denominated in the Euro, Norwegian Krone and Hungarian Forint. As of July 1, 2023, the contracts had maturities of two 4. Derivative Financial Instruments (Continued) Non-designated Hedges Foreign Currency Forward Contracts The Company uses foreign currency forward contracts to reduce the earnings impact that exchange rate fluctuations have on non-U.S. dollar balance sheet exposures. The Company recognizes gains and losses on the foreign currency forward contracts in interest income and other, net in the Consolidated Statement of Income in the same period as the remeasurement loss and gain of the related foreign currency denominated asset or liability. The Company does not apply hedge accounting to these foreign currency forward contracts. As of July 1, 2023, the Company held foreign currency forward contracts denominated in Hungarian Forint and Singapore Dollars with an aggregate notional value of $8.1 million. The fair value of the foreign contracts and contract gains and losses recognized in income were not material for any of the periods presented. |
Supplemental Information
Supplemental Information | 6 Months Ended |
Jul. 01, 2023 | |
Supplemental Information | |
Supplemental Information | 5. Supplemental Information The following table shows the details of selected Condensed Consolidated Balance Sheet items (in thousands): Inventories July 1, December 31, 2023 2022 Work in progress $ 120,880 $ 75,112 Finished goods 24,643 25,305 $ 145,523 $ 100,417 Lease income The Company leases a portion of its headquarter facilities to other tenants. Lease income from operating leases was $1.4 million and $3.7 million during the six months ended July 1, 2023 and July 2, 2022, respectively. |
Debt
Debt | 6 Months Ended |
Jul. 01, 2023 | |
Debt | |
Debt | 6. Debt 0.625% Convertible Senior Notes On June 1, 2020, the Company completed a private placement of $535 million principal amount convertible senior notes (the “2025 Notes”). The 2025 Notes bore interest semi-annually at a rate of 0.625% per year and were scheduled to mature on June 15, 2025. On March 22, 2023, the Company issued a notice of redemption for the 2025 Notes. Prior to the redemption, the Company received conversion notices representing $533.6 million principal amount of the notes. The Company paid $533.6 million in cash and issued 0.9 million shares of common stock, as well as $47 thousand in lieu of fractional shares, for the conversions. Notes representing $1.4 million principal amount were redeemed at par, plus accrued interest. All note conversions and redemptions were completed in June 2023. The carrying amount of the 2025 Notes consisted of the following (in thousands): December 31, 2022 Principal $ 534,980 Unamortized debt issuance costs (5,407) Net carrying amount $ 529,573 The 2025 Notes were recorded in convertible debt, net on the Condensed Consolidated Balance Sheet. The effective interest rate for the liability component was 5.336%. The remaining balance of the debt issuance costs was recognized in stockholders’ equity for 2025 Notes that were converted and as debt extinguishment loss for 2025 Notes that were redeemed in the second quarter of fiscal 2023. Interest expense related to the 2025 Notes was comprised of the following (in thousands): Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Contractual interest expense $ 648 $ 839 $ 1,493 $ 1,684 Amortization of debt issuance costs 436 497 960 994 $ 1,084 $ 1,336 $ 2,453 $ 2,678 Credit Facility The Company and certain of its domestic subsidiaries (the “Guarantors”) have a $400 million revolving credit facility, as amended on June 30, 2023, with a maturity date of June 30, 2028. The credit facility includes a $25 million letter of credit sublimit and a $10 million swingline loan sublimit. The Company also has an option to increase the size of the borrowing capacity by up to the greater of an aggregate of $250 million and 100% of EBITDA of the last four fiscal quarters, plus an amount that would not cause a secured net leverage ratio (funded debt secured by assets/EBITDA) to exceed 3.50 to 1.00, subject to certain conditions. 6. Debt (Continued) The credit facility, other than swingline loans, will bear interest at the Adjusted Term Secured Overnight Financing Rate (“SOFR”) plus an applicable margin or, at the option of the Company, a base rate (defined as the highest of the Wells Fargo prime rate, the Federal Funds rate plus 0.50% and the Adjusted Term SOFR plus 1.00%) plus an applicable margin. Swingline loans accrue interest at the base rate plus the applicable margin for base rate loans. The applicable margins for the Adjusted Term SOFR loans range from 1.00% to 1.75% and for base rate loans range from 0.00% to 0.75%, depending in each case, on the leverage ratio as defined in the credit facility. The credit facility contains various conditions, covenants and representations with which the Company must be in compliance in order to borrow funds and to avoid an event of default, including financial covenants that the Company must maintain a consolidated net leverage ratio (funded indebtedness less cash and cash equivalents up to $750 million and divided by EBITDA) of no more than 4.25 to 1, and a minimum interest coverage ratio (EBITDA/interest payments) of no less than 2.50 to 1. As of July 1, 2023, the Company was in compliance with all covenants of the credit facility. The Company’s obligations under the credit facility are guaranteed by the Guarantors and are secured by a security interest in substantially all assets of the Company and the Guarantors. As of July 1, 2023, $80.0 million was outstanding on the credit facility. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jul. 01, 2023 | |
Commitments and Contingencies | |
Commitments and Contingencies | 7. Commitments and Contingencies Litigation The Company is involved in various legal proceedings that have arisen in the normal course of business. While the ultimate results cannot be predicted with certainty, the Company does not expect them to have a material adverse effect on its Condensed Consolidated Financial Statements. |
Revenues
Revenues | 6 Months Ended |
Jul. 01, 2023 | |
Revenues | |
Revenues | 8. Revenues The Company groups its products as Industrial & Commercial or Home & Life based on the target markets they address. The following represents revenue by product category (in thousands): Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Industrial & Commercial $ 165,303 $ 144,144 $ 316,016 $ 270,813 Home & Life 79,563 119,006 175,637 226,151 $ 244,866 $ 263,150 $ 491,653 $ 496,964 A portion of the Company’s sales are made to distributors under agreements allowing certain rights of return and/or price protection related to the final selling price to the end customers. These factors impact the timing and uncertainty of revenues and cash flows. During the three and six months ended July 1, 2023, the Company did no t recognize any revenue related to performance obligations that were satisfied in previous reporting periods. During the three and six months ended July 2, 2022, the Company recognized revenue of $ Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Distributors $ 187,646 $ 211,943 $ 392,518 $ 404,208 Direct customers 57,220 51,207 99,135 92,756 $ 244,866 $ 263,150 $ 491,653 $ 496,964 |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended |
Jul. 01, 2023 | |
Stock-Based Compensation | |
Stock-Based Compensation | 9. Stock-Based Compensation Stock-based compensation costs are based on the fair values on the date of grant for stock awards and stock options and on the date of enrollment for the employee stock purchase plans. The fair values of stock awards (such as restricted stock units (“RSUs”), performance stock units (“PSUs”) and restricted stock awards (“RSAs”)) are estimated based on their intrinsic values. The fair values of market stock awards (“MSUs”) are estimated using a Monte Carlo simulation. The fair values of stock options and employee stock purchase plans are estimated using the Black-Scholes option-pricing model. The following table presents details of stock-based compensation costs recognized in the Condensed Consolidated Statements of Income (in thousands): Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Cost of revenues $ 283 $ 274 $ 582 $ 546 Research and development 8,813 7,703 18,305 14,694 Selling, general and administrative 5,643 6,412 12,490 12,024 14,739 14,389 31,377 27,264 Income tax benefit 2,155 1,371 3,941 3,215 Total $ 12,584 $ 13,018 $ 27,436 $ 24,049 The Company had approximately $140.1 million of total unrecognized compensation cost related to equity grants as of July 1, 2023 that is expected to be recognized over a weighted-average period of approximately 2.2 |
Income Taxes
Income Taxes | 6 Months Ended |
Jul. 01, 2023 | |
Income Taxes | |
Income Taxes | 10. Income Taxes Provision for income taxes includes both domestic and foreign income taxes at the applicable tax rates adjusted for non-deductible expenses, research and development tax credits, global intangible low-taxed income and Subpart F income inclusions and other permanent differences. Income tax expense was $12.3 million and $11.0 million for the three months ended July 1, 2023 and July 2, 2022, resulting in effective tax rates of 53.0% and 33.2%, respectively. Income tax expense was $20.1 million and $22.7 million for the six months ended July 1, 2023 and July 2, 2022, resulting in effective tax rates of 44.6% and 33.5%, respectively. The increase in the effective tax rate for the three and six months ended July 1, 2023 was primarily due to a decrease to forecasted pre-tax book income, as the impact of permanent items is greater when pre-tax book income is lower, partially offset by a discrete state return-to-provision benefit recorded in the recent quarter. Uncertain Tax Positions As of July 1, 2023, the Company had gross unrecognized tax benefits, inclusive of interest, of $5.1 million, all of which would affect the effective tax rate if recognized. During the six months ended July 1, 2023, the Company did not release any unrecognized tax benefits. The Company recognizes interest and penalties related to unrecognized tax benefits in the provision for income taxes. These amounts were not material for any of the periods presented. 10. Income Taxes (Continued) Following the completion of the Norwegian Tax Administration (“NTA”) examination of the Company’s Norwegian subsidiary for income tax matters relating to fiscal years 2013 - 2016, the Company received an assessment from the NTA in December 2017 concerning an adjustment to its 2013 taxable income related to the pricing of an intercompany transaction. The Company is currently appealing the assessment. The adjustment to the pricing of the intercompany transaction results in approximately 141.3 million Norwegian kroner, or $13.1 million, additional Norwegian income tax. The Company disagrees with the NTA’s assessment and believes the Company’s position on this matter is more likely than not to be sustained. The Company plans to exhaust all available administrative remedies, and if unable to resolve this matter through administrative remedies with the NTA, the Company plans to pursue judicial remedies. The Company believes that it has accrued adequate reserves related to all matters contained in tax periods open to examination. Should the Company experience an unfavorable outcome in the NTA matter, however, such an outcome could have a material impact on its financial statements. Tax years 2015 through 2023 remain open to examination by the major taxing jurisdictions in which the Company operates. The Company’s 2021 tax year is currently under examination in India. Although the outcome of tax audits is always uncertain, the Company believes that the results of the examination will not materially impact its financial position or results of operations. The Company is not currently under audit in any other major taxing jurisdiction. The Company does not expect material changes to its gross unrecognized tax benefits in the next 12 months. |
Subsequent Event
Subsequent Event | 6 Months Ended |
Jul. 01, 2023 | |
Subsequent Event | |
Subsequent Event | 11. Subsequent Event In July 2023, the U.S. Treasury Department released IRS Notice 2023-55, which temporarily relieves taxpayers from the application of certain foreign tax credit Treasury regulations until January 1, 2024. The Company estimates that it will recognize a net tax benefit of approximately $3.3 million as a result, most of which will be recognized in the third quarter of 2023. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 6 Months Ended |
Jul. 01, 2023 | |
Significant Accounting Policies | |
Basis of Presentation and Principles of Consolidation | Basis of Presentation and Principles of Consolidation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information included herein contains all normal recurring accruals and adjustments which, in the opinion of management, are necessary to present fairly Silicon Laboratories Inc.’s (the “Company”) financial position, results of its operations, comprehensive income, stockholders’ equity and cash flows. The Condensed Consolidated Balance Sheet as of December 31, 2022 was derived from the Company’s audited Consolidated Financial Statements. All intercompany balances and transactions have been eliminated in consolidation. The condensed consolidated results of operations for the three and six months ended July 1, 2023 are not necessarily indicative of the results to be expected for the full year. These Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial Statements and notes thereto for the year ended December 31, 2022, included in the Company’s Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 1, 2023. The Company prepares financial statements on a 52- or 53-week fiscal year that ends on the Saturday closest to December 31. Fiscal 2023 will have 52 weeks and fiscal 2022 had 52 weeks. In a 52-week year, each fiscal quarter consists of 13 weeks. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Among the significant estimates affecting the financial statements are those related to inventories, goodwill, acquired intangible assets, other long-lived assets, revenue recognition, stock-based compensation and income taxes. Actual results could differ from those estimates, and such differences could be material to the financial statements. The Company periodically reviews the assumptions used in its financial statement estimates. |
Revenue Recognition | Revenue Recognition Revenue is recognized when control of the promised goods or services is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Substantially all of the Company’s contracts with customers contain a single performance obligation, the sale of mixed-signal integrated circuit (“IC”) products. This performance obligation is satisfied when control of the product is transferred to the customer, which typically occurs upon delivery. Unsatisfied performance obligations primarily represent contracts for products with future delivery dates. The Company has opted to not disclose the amount of unsatisfied performance obligations as these contracts have original expected durations of less than one year. The transaction price reflects the Company’s expectations about the consideration it will be entitled to receive from the customer and may include fixed or variable amounts. Variable consideration primarily includes sales made to distributors under agreements allowing certain rights of return, referred to as stock rotation, and credits issued to the distributor due to price protection. The Company estimates variable consideration at the most likely amount to which it expects to be entitled. The estimate is based on information available to the Company, including recent sales activity and pricing data. The Company applies a constraint to its variable consideration estimate which considers both the likelihood of a return and the amount of a potential price concession. Variable consideration that does not meet revenue recognition criteria is deferred. The Company records a right of return asset in prepaid expenses and other current assets for the costs of distributor inventory not meeting revenue recognition criteria. A corresponding deferred revenue and returns liability amount is recorded for unrecognized revenue associated with such costs. The Company’s products carry a one-year replacement warranty. Payments are typically due within 30 days of invoicing and do not include a significant financing component. |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 6 Months Ended |
Jul. 01, 2023 | |
Earnings Per Share | |
Schedule of computation of basic and diluted earnings per share | The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data): Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Net income $ 10,956 $ 22,135 $ 24,923 $ 45,042 Shares used in computing basic earnings per share 31,614 35,722 31,786 36,862 Effect of dilutive securities: Convertible debt and stock-based awards 1,312 882 1,553 1,201 Shares used in computing diluted earnings per share 32,926 36,604 33,339 38,063 Earnings per share: Basic $ 0.35 $ 0.62 $ 0.78 $ 1.22 Diluted $ 0.33 $ 0.60 $ 0.75 $ 1.18 |
Fair Value of Financial Instr_2
Fair Value of Financial Instruments (Tables) | 6 Months Ended |
Jul. 01, 2023 | |
Fair Value of Financial Instruments | |
Summary of valuation of the financial instruments | The following summarizes the valuation of the Company’s financial instruments (in thousands). The tables do not include either cash on hand or assets and liabilities that are measured at historical cost or any basis other than fair value. Fair Value Measurements at July 1, 2023 Using Quoted Prices in Significant Other Active Markets for Observable Identical Assets Inputs Description (Level 1) (Level 2) Total Cash equivalents: Money market funds $ 129,878 $ — $ 129,878 Total cash equivalents $ 129,878 $ — $ 129,878 Short-term investments: Corporate debt securities $ — $ 178,843 $ 178,843 Government debt securities — 92,220 92,220 Total short-term investments $ — $ 271,063 $ 271,063 Total $ 129,878 $ 271,063 $ 400,941 Fair Value Measurements at December 31, 2022 Using Quoted Prices in Significant Other Active Markets for Observable Identical Assets Inputs Description (Level 1) (Level 2) Total Cash equivalents: Money market funds $ 310,969 $ — $ 310,969 Corporate debt securities — 3,249 3,249 Total cash equivalents $ 310,969 $ 3,249 $ 314,218 Short-term investments: Corporate debt securities $ — $ 501,014 $ 501,014 Government debt securities — 191,010 191,010 Total short-term investments $ — $ 692,024 $ 692,024 Total $ 310,969 $ 695,273 $ 1,006,242 |
Schedule of maturities of the Company's available-for-sale investments and money market funds | The Company’s available-for-sale investments are reported at fair value, with unrealized gains and losses, net of tax, recorded as a component of accumulated other comprehensive loss in the Condensed Consolidated Balance Sheet. The following summarizes the contractual underlying maturities of the Company’s available-for-sale investments at July 1, 2023 (in thousands): Fair Cost Value Due in one year or less $ 187,356 $ 184,252 Due after one year through five years 88,385 86,811 $ 275,741 $ 271,063 |
Schedule of available-for-sale investments in continuous unrealized loss position | The available-for-sale investments that were in a continuous unrealized loss position, aggregated by length of time that individual securities have been in a continuous loss position, were as follows (in thousands): Less Than 12 Months 12 Months or Greater Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized As of July 1, 2023 Value Losses Value Losses Value Losses Corporate debt securities $ 12,019 $ (29) $ 144,341 $ (2,918) $ 156,360 $ (2,947) Government debt securities 50,211 (391) 42,008 (1,415) 92,219 (1,806) $ 62,230 $ (420) $ 186,349 $ (4,333) $ 248,579 $ (4,753) Less Than 12 Months 12 Months or Greater Total Gross Gross Gross Fair Unrealized Fair Unrealized Fair Unrealized As of December 31, 2022 Value Losses Value Losses Value Losses Corporate debt securities $ 307,085 $ (5,297) $ 185,467 $ (4,090) $ 492,552 $ (9,387) Government debt securities 76,651 (626) 100,209 (3,541) 176,860 (4,167) $ 383,736 $ (5,923) $ 285,676 $ (7,631) $ 669,412 $ (13,554) |
Supplemental Information (Table
Supplemental Information (Tables) | 6 Months Ended |
Jul. 01, 2023 | |
Supplemental Information | |
Schedule of Inventories | The following table shows the details of selected Condensed Consolidated Balance Sheet items (in thousands): Inventories July 1, December 31, 2023 2022 Work in progress $ 120,880 $ 75,112 Finished goods 24,643 25,305 $ 145,523 $ 100,417 |
Debt (Tables)
Debt (Tables) | 6 Months Ended |
Jul. 01, 2023 | |
Debt | |
Schedule of information about the equity and liability components of convertible debt | The carrying amount of the 2025 Notes consisted of the following (in thousands): December 31, 2022 Principal $ 534,980 Unamortized debt issuance costs (5,407) Net carrying amount $ 529,573 |
Schedule of components of interest expense | The 2025 Notes were recorded in convertible debt, net on the Condensed Consolidated Balance Sheet. The effective interest rate for the liability component was 5.336%. The remaining balance of the debt issuance costs was recognized in stockholders’ equity for 2025 Notes that were converted and as debt extinguishment loss for 2025 Notes that were redeemed in the second quarter of fiscal 2023. Interest expense related to the 2025 Notes was comprised of the following (in thousands): Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Contractual interest expense $ 648 $ 839 $ 1,493 $ 1,684 Amortization of debt issuance costs 436 497 960 994 $ 1,084 $ 1,336 $ 2,453 $ 2,678 |
Revenues (Tables)
Revenues (Tables) | 6 Months Ended |
Jul. 01, 2023 | |
Revenues | |
Schedule of disaggregation of revenue | The following represents revenue by product category (in thousands): Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Industrial & Commercial $ 165,303 $ 144,144 $ 316,016 $ 270,813 Home & Life 79,563 119,006 175,637 226,151 $ 244,866 $ 263,150 $ 491,653 $ 496,964 Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Distributors $ 187,646 $ 211,943 $ 392,518 $ 404,208 Direct customers 57,220 51,207 99,135 92,756 $ 244,866 $ 263,150 $ 491,653 $ 496,964 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 6 Months Ended |
Jul. 01, 2023 | |
Stock-Based Compensation | |
Schedule of stock-based compensation costs recognized in the Condensed Consolidated Statements of Income | The following table presents details of stock-based compensation costs recognized in the Condensed Consolidated Statements of Income (in thousands): Three Months Ended Six Months Ended July 1, July 2, July 1, July 2, 2023 2022 2023 2022 Cost of revenues $ 283 $ 274 $ 582 $ 546 Research and development 8,813 7,703 18,305 14,694 Selling, general and administrative 5,643 6,412 12,490 12,024 14,739 14,389 31,377 27,264 Income tax benefit 2,155 1,371 3,941 3,215 Total $ 12,584 $ 13,018 $ 27,436 $ 24,049 |
Significant Accounting Polici_3
Significant Accounting Policies (Details) | 6 Months Ended | 12 Months Ended |
Jul. 01, 2023 | Dec. 31, 2022 | |
Significant Accounting Policies | ||
Length of fiscal year | 364 days | 364 days |
Number of days in each fiscal quarter for 52-week fiscal year | 91 days | |
Minimum | ||
Significant Accounting Policies | ||
Length of fiscal year | 364 days | |
Maximum | ||
Significant Accounting Policies | ||
Length of fiscal year | 371 days |
Earnings Per Share (Details)
Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jul. 01, 2023 | Jul. 02, 2022 | Jul. 01, 2023 | Jul. 02, 2022 | |
Earnings Per Share: | |||||
Net income | $ 10,956 | $ 22,135 | $ 24,923 | $ 45,042 | |
Shares used in computing basic earnings per share | 31,614 | 35,722 | 31,786 | 36,862 | |
Effect of dilutive securities: | |||||
Convertible debt and stock-based awards | 1,312 | 882 | 1,553 | 1,201 | |
Shares used in computing diluted earnings per share | 32,926 | 36,604 | 33,339 | 38,063 | |
Earnings per share: | |||||
Basic (in dollars per share) | $ 0.35 | $ 0.62 | $ 0.78 | $ 1.22 | |
Diluted (in dollars per share) | $ 0.33 | $ 0.60 | $ 0.75 | $ 1.18 | |
Shares attributable to dilutive effect of conversion of debt securities | 900 | 600 | 1,100 | 800 | |
0.625% Convertible Senior Notes (2025 Notes) | |||||
Earnings per share: | |||||
Repayment of convertible senior notes | $ 535,000 | ||||
Number of shares of common stock issued in connection with redemption of convertible senior notes | 900 |
Fair Value of Financial Instr_3
Fair Value of Financial Instruments - Valuation of financial instruments (Details) - USD ($) $ in Thousands | Jul. 01, 2023 | Dec. 31, 2022 |
Fair Value of Financial Instruments | ||
Cash equivalents | $ 129,878 | $ 314,218 |
Short-term investments | 271,063 | 692,024 |
Total | 400,941 | 1,006,242 |
Money market funds | ||
Fair Value of Financial Instruments | ||
Cash equivalents | 129,878 | 310,969 |
Corporate debt securities | ||
Fair Value of Financial Instruments | ||
Cash equivalents | 3,249 | |
Short-term investments | 178,843 | 501,014 |
Government debt securities | ||
Fair Value of Financial Instruments | ||
Short-term investments | 92,220 | 191,010 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | ||
Fair Value of Financial Instruments | ||
Cash equivalents | 129,878 | 310,969 |
Total | 129,878 | 310,969 |
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds | ||
Fair Value of Financial Instruments | ||
Cash equivalents | 129,878 | 310,969 |
Significant Other Observable Inputs (Level 2) | ||
Fair Value of Financial Instruments | ||
Cash equivalents | 3,249 | |
Short-term investments | 271,063 | 692,024 |
Total | 271,063 | 695,273 |
Significant Other Observable Inputs (Level 2) | Corporate debt securities | ||
Fair Value of Financial Instruments | ||
Cash equivalents | 3,249 | |
Short-term investments | 178,843 | 501,014 |
Significant Other Observable Inputs (Level 2) | Government debt securities | ||
Fair Value of Financial Instruments | ||
Short-term investments | $ 92,220 | $ 191,010 |
Fair Value of Financial Instr_4
Fair Value of Financial Instruments - Contractual maturities of investments (Details) $ in Thousands | Jul. 01, 2023 USD ($) |
Cost | |
Due in one year or less, Cost | $ 187,356 |
Due after one year through five years, Cost | 88,385 |
Total Cost | 275,741 |
Fair Value | |
Due in one year or less, Fair Value | 184,252 |
Due after one year through five years, Fair Value | 86,811 |
Total Fair Value | $ 271,063 |
Fair Value of Financial Instr_5
Fair Value of Financial Instruments - Unrealized Gains and Losses (Details) - USD ($) $ in Thousands | Jul. 01, 2023 | Dec. 31, 2022 |
Continuous unrealized loss position, Fair Value | ||
Fair value of available-for-sale investments, continuous loss position for less than twelve months | $ 62,230 | $ 383,736 |
Fair value of available-for-sale investments, continuous loss position for twelve months or greater | 186,349 | 285,676 |
Total fair value of available-for-sale investments, continuous loss position | 248,579 | 669,412 |
Continuous unrealized loss position, Gross Unrealized Losses | ||
Available-for-sale investments, continuous loss position for less than 12 months, gross unrealized losses | (420) | (5,923) |
Available-for-sale investments, continuous loss position for 12 months or greater, gross unrealized losses | (4,333) | (7,631) |
Available-for-sale investments, total gross unrealized losses | (4,753) | (13,554) |
Corporate debt securities | ||
Continuous unrealized loss position, Fair Value | ||
Fair value of available-for-sale investments, continuous loss position for less than twelve months | 12,019 | 307,085 |
Fair value of available-for-sale investments, continuous loss position for twelve months or greater | 144,341 | 185,467 |
Total fair value of available-for-sale investments, continuous loss position | 156,360 | 492,552 |
Continuous unrealized loss position, Gross Unrealized Losses | ||
Available-for-sale investments, continuous loss position for less than 12 months, gross unrealized losses | (29) | (5,297) |
Available-for-sale investments, continuous loss position for 12 months or greater, gross unrealized losses | (2,918) | (4,090) |
Available-for-sale investments, total gross unrealized losses | (2,947) | (9,387) |
Government debt securities | ||
Continuous unrealized loss position, Fair Value | ||
Fair value of available-for-sale investments, continuous loss position for less than twelve months | 50,211 | 76,651 |
Fair value of available-for-sale investments, continuous loss position for twelve months or greater | 42,008 | 100,209 |
Total fair value of available-for-sale investments, continuous loss position | 92,219 | 176,860 |
Continuous unrealized loss position, Gross Unrealized Losses | ||
Available-for-sale investments, continuous loss position for less than 12 months, gross unrealized losses | (391) | (626) |
Available-for-sale investments, continuous loss position for 12 months or greater, gross unrealized losses | (1,415) | (3,541) |
Available-for-sale investments, total gross unrealized losses | $ (1,806) | $ (4,167) |
Fair Value of Financial Instr_6
Fair Value of Financial Instruments - Fair values of other financial instruments (Details) - USD ($) $ in Millions | Jul. 01, 2023 | Dec. 31, 2022 |
Convertible Senior Notes | Level 2 | ||
Fair Value of Financial Instruments | ||
Fair value of debt | $ 0 | $ 671.9 |
Derivative Financial Instrume_2
Derivative Financial Instruments (Details) - Foreign currency forward contracts $ in Millions | 6 Months Ended |
Jul. 01, 2023 USD ($) | |
Non-designated Hedges | |
Derivative Financial Instruments | |
Derivative, notional amount | $ 8.1 |
Cash flow hedges | |
Derivative Financial Instruments | |
Derivative, notional amount | $ 10.3 |
Cash flow hedges | Minimum | |
Derivative Financial Instruments | |
Maturity of contracts | 2 months |
Cash flow hedges | Maximum | |
Derivative Financial Instruments | |
Maturity of contracts | 6 months |
Supplemental Information (Detai
Supplemental Information (Details) - USD ($) $ in Thousands | 6 Months Ended | ||
Jul. 01, 2023 | Jul. 02, 2022 | Dec. 31, 2022 | |
Inventories | |||
Work in progress | $ 120,880 | $ 75,112 | |
Finished goods | 24,643 | 25,305 | |
Inventories | 145,523 | $ 100,417 | |
Lease income | |||
Lease income | $ 1,400 | $ 3,700 | |
Lease income, Statements of Income location | Selling, general and administrative | Selling, general and administrative |
Debt - Convertible Senior Notes
Debt - Convertible Senior Notes (Details) - 0.625% Convertible Senior Notes (2025 Notes) - USD ($) $ in Thousands, shares in Millions | 1 Months Ended | ||
Jun. 30, 2023 | Mar. 22, 2023 | Jun. 01, 2020 | |
Debt | |||
Principal amount | $ 533,600 | $ 535,000 | |
Semi-annual interest rate (as a percent) | 0.625% | ||
Repayment of convertible senior notes including conversions and redemptions | $ 533,600 | ||
Number of shares of common stock issued in connection with redemption of convertible senior notes | 0.9 | ||
Payments made in lieu of fractional shares | $ 47 | ||
Principal amount were redeemed at par, plus accrued interest | $ 1,400 |
Debt - Convertible Debt, Net (D
Debt - Convertible Debt, Net (Details) - 0.625% Convertible Senior Notes (2025 Notes) - USD ($) $ in Thousands | Jul. 01, 2023 | Dec. 31, 2022 |
Liability component | ||
Principal | $ 534,980 | |
Unamortized debt issuance costs | (5,407) | |
Net carrying amount | $ 529,573 | |
Effective interest rate | 5.336% |
Debt - Interest expense (Detail
Debt - Interest expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 01, 2023 | Jul. 02, 2022 | Jul. 01, 2023 | Jul. 02, 2022 | |
Interest expense related to the notes | ||||
Interest Expense, Total | $ 1,596 | $ 1,667 | $ 3,252 | $ 3,347 |
Convertible Senior Notes | ||||
Interest expense related to the notes | ||||
Contractual interest expense | 648 | 839 | 1,493 | 1,684 |
Amortization of debt issuance costs | 436 | 497 | 960 | 994 |
Interest Expense, Total | $ 1,084 | $ 1,336 | $ 2,453 | $ 2,678 |
Debt - Credit Facility (Details
Debt - Credit Facility (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jul. 01, 2023 | Jun. 30, 2023 | |
Debt | ||
Cash and cash eqquivalents used in net leverage ratio | $ 750 | |
Credit Facility | ||
Debt | ||
Amount outstanding | 80 | |
Credit Facility | Scenario: Company's option to increase borrowing capacity | ||
Debt | ||
Additional increase in borrowing capacity of the line of credit available at the entity's option | $ 250 | |
Additional increase in borrowing capacity based on EBITDA (as a percent) | 100% | |
Maximum secured net leverage ratio | 3.50 | |
Credit Facility | Scenario: Credit facility debt covenants | ||
Debt | ||
Maximum net leverage ratio | 4.25 | |
Maximum secured leverage ratio | 2.50 | |
Revolving Credit Facility | ||
Debt | ||
Maximum borrowing capacity | $ 400 | |
Revolving credit facility, other than swingline loans | Federal Funds Rate | ||
Debt | ||
Interest rate margin (as a percent) | 0.50% | |
Revolving credit facility, other than swingline loans | SOFR | ||
Debt | ||
Interest rate margin (as a percent) | 1% | |
Revolving credit facility, other than swingline loans | SOFR | Minimum | ||
Debt | ||
Interest rate margin (as a percent) | 1% | |
Revolving credit facility, other than swingline loans | SOFR | Maximum | ||
Debt | ||
Interest rate margin (as a percent) | 1.75% | |
Revolving credit facility, other than swingline loans | Base Rate | Minimum | ||
Debt | ||
Interest rate margin (as a percent) | 0% | |
Revolving credit facility, other than swingline loans | Base Rate | Maximum | ||
Debt | ||
Interest rate margin (as a percent) | 0.75% | |
Letter of Credit | ||
Debt | ||
Maximum borrowing capacity | $ 25 | |
Swingline Loans | ||
Debt | ||
Maximum borrowing capacity | $ 10 |
Revenues (Details)
Revenues (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 01, 2023 | Jul. 02, 2022 | Jul. 01, 2023 | Jul. 02, 2022 | |
Revenues | ||||
Revenues | $ 244,866 | $ 263,150 | $ 491,653 | $ 496,964 |
Revenue from performance obligations that were satisfied in previous reporting periods | 0 | 36,500 | 0 | 32,000 |
Distributors | ||||
Revenues | ||||
Revenues | 187,646 | 211,943 | 392,518 | 404,208 |
Direct customers | ||||
Revenues | ||||
Revenues | 57,220 | 51,207 | 99,135 | 92,756 |
Industrial & Commercial | ||||
Revenues | ||||
Revenues | 165,303 | 144,144 | 316,016 | 270,813 |
Home & Life | ||||
Revenues | ||||
Revenues | $ 79,563 | $ 119,006 | $ 175,637 | $ 226,151 |
Stock-Based Compensation (Detai
Stock-Based Compensation (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 01, 2023 | Jul. 02, 2022 | Jul. 01, 2023 | Jul. 02, 2022 | |
Stock-based compensation costs | ||||
Stock based compensation costs | $ 14,739 | $ 14,389 | $ 31,377 | $ 27,264 |
Income tax benefit | 2,155 | 1,371 | 3,941 | 3,215 |
Share based compensation costs after tax | 12,584 | 13,018 | 27,436 | 24,049 |
Total unrecognized compensation costs related to awards | 140,100 | $ 140,100 | ||
Weighted-average period of recognition of unrecognized compensation costs | 2 years 2 months 12 days | |||
Cost of revenues | ||||
Stock-based compensation costs | ||||
Stock based compensation costs | 283 | 274 | $ 582 | 546 |
Research and development | ||||
Stock-based compensation costs | ||||
Stock based compensation costs | 8,813 | 7,703 | 18,305 | 14,694 |
Selling, general and administrative | ||||
Stock-based compensation costs | ||||
Stock based compensation costs | $ 5,643 | $ 6,412 | $ 12,490 | $ 12,024 |
Income Taxes (Details)
Income Taxes (Details) $ in Thousands, kr in Millions | 3 Months Ended | 6 Months Ended | |||
Jul. 01, 2023 USD ($) | Jul. 02, 2022 USD ($) | Jul. 01, 2023 USD ($) | Jul. 01, 2023 NOK (kr) | Jul. 02, 2022 USD ($) | |
Income Taxes | |||||
Income tax expense (benefit) | $ 12,338 | $ 10,994 | $ 20,091 | $ 22,683 | |
Effective income tax rate (as a percent) | 53% | 33.20% | 44.60% | 44.60% | 33.50% |
Gross unrecognized tax benefits which would affect the effective tax rate if recognized | $ 5,100 | $ 5,100 | |||
Norwegian Tax Administration | 2013 | Under appeal | |||||
Income Taxes | |||||
Estimate of additional income tax expense | $ 13,100 | kr 141.3 |
Subsequent Event (Details)
Subsequent Event (Details) $ in Millions | 3 Months Ended |
Sep. 30, 2023 USD ($) | |
Subsequent Event | |
Subsequent Event | |
Expected net tax benefit | $ 3.3 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Jul. 01, 2023 shares | |
Trading Arrangements, by Individual | |
Material Terms of Trading Arrangement | Rule 10b5-1 Trading Arrangements The following table describes contracts, instructions or written plans for the purchase or sale of our securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) entered into during the quarter ended July 1, 2023. There were no non-Rule 10b5-1 trading arrangements entered into during the quarter ended July 1, 2023. Aggregate Number of Securities to be Date of Purchased or Sold Adoption of Duration of the Pursuant to the Name and Title of Director or Officer Arrangement Arrangement Arrangement R. Matthew Johnson President and Chief Executive Officer May 1, 2023 Expires December 29, 10,711 John C. Hollister Senior Vice President and Chief Financial Officer May 15, 2023 Expires April 26, 26,000 |
Non-Rule 10b5-1 Arrangement Adopted | false |
R Matthew Johnson [Member] | |
Trading Arrangements, by Individual | |
Name | R. Matthew Johnson |
Title | President and Chief Executive Officer |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | May 01, 2023 |
Aggregate Available | 10,711 |
Expiration Date | Dec. 29, 2023 |
John C Hollister [Member] | |
Trading Arrangements, by Individual | |
Name | John C. Hollister |
Title | Senior Vice President and Chief Financial Officer |
Rule 10b5-1 Arrangement Adopted | true |
Adoption Date | May 15, 2023 |
Aggregate Available | 26,000 |
Expiration Date | Apr. 26, 2024 |